Novartis: Glomerulonephritis, IGA trials

The registry lists 18 Glomerulonephritis, IGA studies with Novartis as lead sponsor. 10 are open to participants now and 3 have results posted.

Phase 1 1Phase 2 6Phase 3 8No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA NephropathyNot yet recruitingNCT07850752Phase 3
• Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgANRecruitingNCT07498335Phase 3
• IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using Primary Data CollectionNot yet recruitingNCT07481084
• Managed Access Programs for EXV811, AtrasentanAvailableNCT07319585
• A Study to Assess the Effects of Zigakibart on IgA Nephropathy.RecruitingNCT07146906Phase 2
• Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANRecruitingNCT06994845Phase 3
• A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the USRecruitingNCT06952426
• Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.RecruitingNCT06858319Phase 3
• Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgANRecruitingNCT06797518Phase 2
• A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA NephropathyRecruitingNCT04557462Phase 3
• Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA NephropathyCompletedNCT05834738Phase 2Results posted
• Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy PatientsCompletedNCT04578834Phase 3Results posted
• Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by InflammationCompletedNCT03373461Phase 2Results posted
• A Study of Treatment Patterns and Real-World Outcomes in IgA Nephropathy Patients in the United StatesCompletedNCT07757048
• A Study of Zigakibart in Adults With IgA NephropathyActive, not recruitingNCT05852938Phase 3
• Atrasentan in Patients With Proteinuric Glomerular DiseasesActive, not recruitingNCT04573920Phase 2
• Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Phase 3
• Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)CompletedNCT03945318Phase 1/2